Natural lipids containing non-oxidizable fatty acids

Abstract

Provided herein is technology relating to natural lipids containing non-β-oxidizable fatty acids and particularly, but not exclusively, to compositions and methods related to the production and use of natural lipids containing non-β-oxidizable fatty acids.

1 . A structured phospholipid composition comprising phospholipid molecules of the following structure: 
       
         
           
           
               
               
           
         
         wherein one of R1 and R2 is a non-beta-oxidizable fatty acid analogue moiety and the other of R1 and R2 is a bioactive fatty acid moiety selected from the group consisting of an omega-3 fatty acid moiety, on omega-6 fatty acid moiety, a polyunsaturated fatty acid moiety, a conjugated linoleic fatty acid moiety, and combinations thereof, and R3 is a choline, ethanolamine, serine or inositol group. 
       
     
     
         2 . The structured phospholipid composition of  claim 1 , wherein said composition comprises greater than 10%, 20%, 30%, 40%, 50%, 80%, 90% or 99% on a molar basis of said non-beta-oxidizable fatty acid analogue moiety at position R1. 
     
     
         3 . The structured phospholipid composition of  claim 1 , wherein said composition comprises greater than 50%, 80%, 90% or 99% on a molar basis of said non-beta-oxidizable fatty acid analogue moiety at position R2. 
     
     
         4 . The structured phospholipid composition of  claim 1 , comprising greater than about 50%, 80%, 90% or 99% on a molar basis of said bioactive fatty acid moieties or combinations thereof at position R2. 
     
     
         5 . The structured phospholipid composition of  claim 1 , comprising greater than about 50%, 80%, 90% or 99% on a molar basis of said bioactive fatty acid moiety at position R1. 
     
     
         6 . The structured phospholipid composition of  claim 4 , wherein said bioactive fatty acid moiety is selected from the group consisting of EPA, DHA and a combination thereof. 
     
     
         7 . The structured phospholipid composition of  claim 4 , wherein said bioactive fatty acid moiety is EPA. 
     
     
         8 . The structured phospholipid composition of  claim 4 , wherein said bioactive fatty acid moiety is DHA. 
     
     
         9 . The structured phospholipid composition of  claim 4 , wherein said bioactive fatty acid moiety is conjugated linoleic acid. 
     
     
         10 . A pharmaceutical composition comprising the structured lipid of  claim 1  and a pharmaceutically acceptable carrier. 
     
     
         11 . The pharmaceutical composition of  claim 10  wherein the structured lipid comprises TTA. 
     
     
         12 . The pharmaceutical composition of  claim 10  wherein structured lipid comprises an ether link between a lipid tail and a lipid headgroup. 
     
     
         13 . The pharmaceutical composition according to  claim 10 , admixed with at least one of a pharmaceutically acceptable carrier, diluent, excipient, or adjuvant.